ZRSR2 and acute myeloid leukemia: DNMT3A mutations were detected more frequently in pDC-AML than BPDCN (32% versus 10%, p = 0.0079), and ZRSR2 mutations occurred less frequently in pDC-AML than BPDCN (2% versus 16%, p = 0.03).